{
    "clinical_study": {
        "@rank": "166568", 
        "arm_group": [
            {
                "arm_group_label": "oMP 1250 mg: Group A", 
                "arm_group_type": "Active Comparator", 
                "description": "Methylprednisolone 1250 mg/24h x3 days"
            }, 
            {
                "arm_group_label": "oMP 625 mg: Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "Methylprednisolone oral 625 mg/24h x3 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators plan to carry out a multicenter randomized clinical trial and MRI study of\n      high-dose oMP (1250mg/day for 3 days) versus lower-high dose oMP (625mg/day for 3 days) and\n      demonstrated that lower-high dose of oMP is as effective as a higher-high dose of oMP in\n      acute relapse of multiple sclerosis (MS). If it is shown, our purpose is to promote this\n      therapeutic regimen because it is safer for the patient (less adverse effects) and less\n      costly to the healthcare system."
        }, 
        "brief_title": "Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "DESIGN: Phase IV clinical trial, multicentre, randomized and double blind, active drug\n      controlled and parallel groups.  Patients will be randomised to a high dose of oMP vs a\n      lower-high dose of oral Methylprednisolone (oMP).\n\n      SETTING: 9 MS Units from 9 hospitals of the public health system with extensive experience\n      in treating patients with MS and design and participation in clinical trials.\n\n      PROCEDURES:\n\n      After signing the informed consent, the inclusion and exclusion criteria specific to the\n      study will be checked. The diagnostic test will take place prior to administration of study\n      medication and will include medical history, neurological examination (EDSS measurement)\n      taking of vital signs (blood pressure, heart rate and body temperature) and MRI. Concomitant\n      medication will be checked. Patients will be instructed about the requirements during the\n      study.\n\n      The trial medication will be provided to the patient in the medical office (day 1 of the\n      study), where the patient will remain until the intake. This action will be repeated the\n      following 2 days. The latency period from the beginning of the relapse until the start of\n      treatment will be registered. The questionnaires of tolerance will be completed.\n\n      Day 1 will be defined as the first day on which first dose of oMP is administered.\n\n      Once given the treatment under study, the adverse events reported spontaneously or after\n      question will be collected.\n\n      There will be follow-up visits at 7 and 28 days, and 3 months after initiation of treatment.\n      At baseline, prior to drug administration, and on days 7 and 28 after initiation of\n      treatment, a brain MRI with and without contrast will be performed. In case of adverse\n      events or laboratory abnormalities, the patients could have an accessory follow-up visits\n      until resolution.\n\n      Randomization will be performed on the day of administration (day 1)\n\n      The treatments are:\n\n      Group A: Methylprednisolone 1250 mg / day orally for 3 days Group B: Methylprednisolone\n      625 mg / day orally for 3 days"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Relapsing-remitting MS (Mc Donald criteria 2010) regardless being under\n             immunomodulatory treatment\n\n          2. EDSS (previous to relapse) between 0 and 5\n\n          3. MS relapse of moderate intensity (EDSS increase from 1 to 2.5 points) or severe\n             intensity (EDSS increase > 3 points)\n\n               -  If EDSS previous relapse is available:\n\n                    -  optic neuritis, myelitis or brainstem relapse: the EDSS should increase of\n                       1 point in visual, pyramidal or brainstem system function\n\n                    -  relapse in other location or uncertain location: the EDSS should increase\n                       at least 1 point\n\n               -  If EDSS previous relapse is not available:\n\n                    -  optic neuritis, myelitis or brainstem relapse: the visual, pyramidal or\n                       brainstem system function should be > 2 points.\n\n                    -  relapse in other location or uncertain location: EDSS should be > 2 points\n\n          4. Recent clinical relapse onset (<15 days) without fever\n\n          5. One month of clinical stability prior to relapse\n\n          6. Signed informed consent\n\n          7. Capacity to ingest the medication.\n\n        Exclusion Criteria:\n\n          1. Doubts about the diagnosis of multiple sclerosis\n\n          2. First episode of inflammatory neurological disease\n\n          3. Secondary progressive MS or primary progressive MS\n\n          4. Symptoms with lasted less than 24 hours of evolution\n\n          5. Any degree of subjective or objective remission\n\n          6. Treatment with corticosteroids during the previous 30 days\n\n          7. Patients with immunosuppressive treatment (azathioprine, mitoxantrone,\n             cyclophosphamide) or Natalizumab or Fingolimod\n\n          8. Pregnancy or breastfeeding women or women of childbearing potential not using\n             contraceptive measures\n\n          9. Diseases with a contraindication of treatment with corticosteroids\n\n         10. History of serious adverse reaction or hypersensitivity to drugs related to study\n             medication\n\n         11. Patients who could not be regular MRI, not collaborators or who requires anesthesia.\n\n         12. Lactose intolerance\n\n         13. Patients with allergies to contrast used in MRI\n\n         14. Patients with renal impairment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "59 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986998", 
            "org_study_id": "oral-CORTEM", 
            "secondary_id": "2012-001965-34"
        }, 
        "intervention": [
            {
                "arm_group_label": "oMP 1250 mg: Group A", 
                "description": "Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)", 
                "intervention_name": "Methylprednisolone 1250 mg/24h x3 days", 
                "intervention_type": "Drug", 
                "other_name": "Group A"
            }, 
            {
                "arm_group_label": "oMP 625 mg: Group B", 
                "description": "Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)", 
                "intervention_name": "Oral Methylprednisolone 625 mg/24h x3 days", 
                "intervention_type": "Drug", 
                "other_name": "Group B"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple sclerosis relapse", 
            "oral methylprednisolone", 
            "EDSS", 
            "gadolinium"
        ], 
        "lastchanged_date": "November 18, 2013", 
        "location": [
            {
                "contact": {
                    "email": "cramot@gmail.com", 
                    "last_name": "Cristina Ramo, MD", 
                    "phone": "93 497 88 62"
                }, 
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08916"
                    }, 
                    "name": "Hospital Universitari Germans Trias I Pujol de"
                }, 
                "investigator": [
                    {
                        "last_name": "Cristina Ramo, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Joan Costa, MD,PhDClinical Pharmacologist", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pilar Giner, PhDPharmacist", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Laia Grau, MD. PhDNeurologist", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Eva Montan\u00e9, MDClinical Pharmacologist", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Eva Mart\u00ednez-C\u00e1ceres, MD,PhDImmunologist", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ocarmona@salutemporda.cat", 
                    "last_name": "Olga Carmona, MD,PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Figueres", 
                        "country": "Spain", 
                        "state": "Girona", 
                        "zip": "17600"
                    }, 
                    "name": "Hospital de Figueres"
                }, 
                "investigator": {
                    "last_name": "Olga Carmona, MD, PhDNeurologist", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "YBLANCO@clinic.ub.es", 
                    "last_name": "Yolanda Blanco, MD,PhD", 
                    "phone": "93 227 54 12"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Clinic I Provincial de Barcelona"
                }, 
                "investigator": {
                    "last_name": "Yolanda Blanco, MD, PhDNeurologist", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "acano@csdm.cat", 
                    "last_name": "Antonio Cano, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08034"
                    }, 
                    "name": "Hospital de Matar\u00f3"
                }, 
                "investigator": {
                    "last_name": "Antonio Cano, MD. PhDNeurologist", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "EMunteis@parcdesalutmar.cat", 
                    "last_name": "Elvira Munteis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08003"
                    }, 
                    "name": "Hospital Del Mar"
                }, 
                "investigator": {
                    "last_name": "Elvira Munteis, MDNeurologist", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "estermoral@yahoo.es", 
                    "last_name": "Esther del Moral, MD,PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital de Sant Joan Desp\u00ed Mois\u00e9s Broggi"
                }, 
                "investigator": {
                    "last_name": "Esther del Moral, MD, PhDNeurologist", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "llramio.girona.ics@gencat.cat", 
                    "last_name": "Lluis Rami\u00f3, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Girona", 
                        "country": "Spain", 
                        "zip": "17007"
                    }, 
                    "name": "Hospital Universitari de Girona Dr. Josep Trueta"
                }, 
                "investigator": {
                    "last_name": "Lluis Rami\u00f3, MD. PhDNeurologist", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "brievaluis@hotmail.com", 
                    "last_name": "Luis Brieva, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lleida", 
                        "country": "Spain", 
                        "zip": "25198"
                    }, 
                    "name": "Hospital Universitari Arnau de Vilanova de Lleida"
                }, 
                "investigator": {
                    "last_name": "Luis Brieva, MD. PhDNeurologist", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jbatlle@xarxatecla.cat", 
                    "last_name": "Jordi Batlle, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tarragona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital de Sant Pau I Santa Tecla"
                }, 
                "investigator": {
                    "last_name": "Jordi Batlle, MD. PhDNeurologist", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Randomized, Double-blind Clinical Trial to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse.", 
        "overall_contact": {
            "email": "cramot@gmail.com", 
            "last_name": "Cristina Ramo, MD", 
            "phone": "93 497 88 62"
        }, 
        "overall_official": {
            "affiliation": "Germans Trias i Pujol Hospital", 
            "last_name": "Cristina Ramo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disability scale of Kurtzke EDSS score", 
            "safety_issue": "Yes", 
            "time_frame": "up to day 91"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986998"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Germans Trias i Pujol Hospital", 
            "investigator_full_name": "Cristina Ramo", 
            "investigator_title": "Cristina Ramo", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse events / tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and day 29"
            }, 
            {
                "measure": "Disability scale of Kurtzke EDSS score", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and day 8"
            }, 
            {
                "measure": "The number and volume of active lesions (measured by the T2 or gadolinium enhancement), the number of new active lesions and the percentage of active lesions at baseline that becomes black holes", 
                "safety_issue": "No", 
                "time_frame": "day -1 and day 29"
            }, 
            {
                "measure": "Adverse events / tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and day 8"
            }, 
            {
                "measure": "Questionnaire MSQOL-54", 
                "safety_issue": "No", 
                "time_frame": "Baseline and day 8"
            }, 
            {
                "measure": "Questionnaire MSQOL-54", 
                "safety_issue": "No", 
                "time_frame": "Baseline and day 29"
            }
        ], 
        "source": "Germans Trias i Pujol Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Germans Trias i Pujol Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}